We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Highlights Cutting-Edge Diagnostic Products and Solutions

By LabMedica International staff writers
Posted on 23 Jul 2023

Randox Laboratories (Crumlin, UK) is exhibiting its cutting-edge diagnostic products and solutions at 2023 AACC, while also highlighting its groundbreaking technologies.

As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including quality control, molecular diagnostics, third-party reagents, point of care, and clinical chemistry analyzers. With an extensive product range offering expansive third-party quality controls and calibrators, inter-laboratory data management, external quality assessments, and calibration verification. Randox’s new Acusera Quality Controls for 2022/2023 highlighted at the show include Active B12, Anti Mullerian Hormone (AMH), Brain Natriuretic Peptide (BNP) Control, Bone Markers (Serum) Control, Pre-eclampsia Control, Serum Indices Control, Ultra-Low PSA Control, Xanthochromia Control.


Image: The world’s first Xylazine ELISA is available on the Evidence MultiSTAT analyzer (Photo courtesy of Randox)
Image: The world’s first Xylazine ELISA is available on the Evidence MultiSTAT analyzer (Photo courtesy of Randox)

At AACC 2023, Randox is also showcasing its recently launched and the world’s first Xylazine ELISA. Xylazine, which is an analgesic drug primarily used within the veterinary industry as a tranquilizer, has not been approved for human use but has been linked to the USA’s illicit drug supply in recent years. While the prevalence of Xylazine is showing no sign of decreasing, Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market. The company’s newly-established test for xylazine is the first immunoassay test in the world for this drug of abuse and is available on the Evidence MultiSTAT analyzer. Evidence MultiSTAT is designed to work across a variety of matrices including blood, and oral fluid, and simultaneously screens for up to 29 drugs of abuse from a single sample in less than 31 minutes.

In recent years, Randox has been expanding its Randox Health testing – bringing preventative healthcare directly to the public. Specializing in ‘Pre-disease’ highly sensitive biomarkers in the blood are measured before an individual start to feel sick and before regular blood tests would show illness. After making the service available throughout the UK and Ireland via its innovative mobile health clinic, Randox is now unveiling Randox Health Labs located in Santa Monica, California at AACC 2023. Randox’s extensive test menu offers over 150 analytes, allowing access some of the most specialized tests available in the market today.

Related Links:
Randox Laboratories 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test

Latest AACC 2023 News

First-of-Its-Kind Single-Cell Clinical Microbiology Platform Wins 2023 Disruptive Technology Award

Ground-Breaking Phage-Based Diagnostic Kit for Laboratory Tuberculosis Testing Presented at AACC 2023

Laboratory Experts Show How They Are Leading the Way on Global Trends